Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, D. H. | - |
dc.contributor.author | Kim, S. -W. | - |
dc.contributor.author | Suh, C. | - |
dc.contributor.author | Lee, J. -S. | - |
dc.contributor.author | Lee, J. H. | - |
dc.contributor.author | Lee, S-J. | - |
dc.contributor.author | Ryoo, B. Y. | - |
dc.contributor.author | Park, K. | - |
dc.contributor.author | Kim, J. S. | - |
dc.contributor.author | Heo, D. S. | - |
dc.contributor.author | Kim, N. K. | - |
dc.date.accessioned | 2021-09-09T12:50:11Z | - |
dc.date.available | 2021-09-09T12:50:11Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2008-01 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/124458 | - |
dc.description.abstract | Background: Belotecan (Camtobell (R), Chong Keun Dang Corp, Seoul, Korea; CKD602) is a new camptothecin analogue. This study aimed to investigate the safety and efficacy of single-agent belotecan for small-cell lung cancer (SCLC). Patients and methods: Twenty-seven patients with chemotherapy-naive or chemosensitive SCLC were treated with belotecan 0.5 mg/m(2)/day on days 1-5 of a 3-week cycle. All 27 patients were assessable for toxicity, and 21 patients assessable for response. Results: Nine patients (42.9%) showed objective tumor responses including one complete response; seven (63.6%) in 11 chemotherapy-naive patients; and two (20.0%) in 10 chemosensitive patients. With a median follow-up of 5 years, median progression-free and survival time for chemotherapy-naive patients were 4.8 months and 11.9 months, respectively, while the corresponding values for chemosensitive patients were 3.3 months and 10.5 months, respectively. The most common toxicity was neutropenia. Conclusion: Belotecan was active in SCLC patients as a single agent, warranting further investigations of belotecan in combination with platinum or other active agents. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.subject | METASTATIC COLORECTAL-CANCER | - |
dc.subject | FLUOROURACIL FAILURE | - |
dc.subject | RANDOMIZED-TRIAL | - |
dc.subject | IRINOTECAN | - |
dc.subject | TOPOTECAN | - |
dc.subject | DISEASE | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | CARCINOMA | - |
dc.subject | CISPLATIN | - |
dc.subject | ETOPOSIDE | - |
dc.title | Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, J. S. | - |
dc.identifier.doi | 10.1093/annonc/mdm437 | - |
dc.identifier.scopusid | 2-s2.0-37849041674 | - |
dc.identifier.wosid | 000253176400019 | - |
dc.identifier.bibliographicCitation | ANNALS OF ONCOLOGY, v.19, no.1, pp.123 - 127 | - |
dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
dc.citation.title | ANNALS OF ONCOLOGY | - |
dc.citation.volume | 19 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 123 | - |
dc.citation.endPage | 127 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | METASTATIC COLORECTAL-CANCER | - |
dc.subject.keywordPlus | FLUOROURACIL FAILURE | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | IRINOTECAN | - |
dc.subject.keywordPlus | TOPOTECAN | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | ETOPOSIDE | - |
dc.subject.keywordAuthor | belotecan | - |
dc.subject.keywordAuthor | single agent | - |
dc.subject.keywordAuthor | small-cell lung cancer | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.